- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Systemic lupus erythematosus (SLE)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Belimumab – November 2019
Belimumab: Injection 200 mg in 1 mL pre-filled pen; Benlysta®
Last updated
20 March 2020